EBMT 2024 | HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors

Rémy Duléry • 15 Apr 2024

EBMT 2024

Human herpesvirus type 6 (HHV-6) reactivation commonly occurs following transplantation and is associated with an increased likelihood of acute graft-versus-host-disease (GvHD) and delayed platelet engraftment. Rémy Duléry, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the findings of a study that aimed to assess whether treatment with post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) following haploidentical hematopoietic stem cell transplantation (SCT) increased the incidence of HHV-6 reactivation. The strongest predictive factor for HHV-6 reactivation in these patients was a low lymphocyte count at day +30. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.